Patents
Sitemap › C07 - Organic chemistry › C07D - Heterocyclic compounds › C07D 491 - Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups , , or
Patents for C07D 491 - Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups , , or (29,726)
03/2003
03/13/2003CA2422135A1 Urea derivatives and adhesion molecule inhibitors containing the same as effective ingredients
03/12/2003EP1289999A1 Antitumoral analogs of et-743
03/12/2003EP1289985A2 Beta-carboline derivatives useful as inhibitors of phosphodiesterase
03/12/2003EP1289525A2 Tricyclic pyrazole derivatives as protein kinase inhibitors
03/12/2003EP1075477B1 Novel Benzonaphthyridine-N-oxides
03/12/2003CN1402721A Benzoimidazole derivs. useful as antiproliferative agents
03/12/2003CN1402643A Integrin-mediated drug targeting
03/12/2003CN1102932C Novel water-soluble analogues of 20(S)-camptothecin, preparing method and use thereof
03/07/2003WO2002020481A2 Substituted 4-phenyl-1-(1-phenyl-cyclohexyl)-1,2,3,6-tetrahydropyridine
03/07/2003CA2421835A1 Substituted 4-phenyl-1-(1-phenyl-cyclohexyl)-1,2,3,6-tetrahydropyridines
03/06/2003WO2003018589A1 Novel 4-aminofuropyrimidines and the use thereof
03/06/2003WO2003018559A2 Intermediates and preparation thereof for the enantioselective synthesis of (20r) homocamptothecins
03/06/2003WO2003017764A1 Substituted propargylamines
03/06/2003WO2003000240A3 Stable powder inhalation dosage formulation
03/06/2003US20030045719 And optionally resolving mixture to obtain the desired enantiomer; antitumor agents
03/06/2003US20030045717 Suitable as fluorescent dyes (fluorophores) for used in optical determination and demonstration methods in medicine, pharmacology and biological and environmental sciences; photostability, storage stability
03/06/2003US20030045714 Photochromic sections being 2H-pyrans and/ or spirooxazines; use in ophthalmic lenses or sun-protection roofs
03/06/2003US20030045711 Epothilone derivatives and methods for making and using the same
03/06/2003US20030045542 Antidepressant azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-dioxino[2,3-f]quinoline
03/06/2003US20030045540 Nicotinic acetylcholine receptors antagonists; central nervous system disorder treatments
03/06/2003US20030045537 4-(Phenylamino)-[1,4]dioxano[2,3-g]quinazoline derivatives and process for preparing the same
03/06/2003US20030045526 Antipsychotic aminomethyl derivatives of 1,3,7,8-tetrahydro-6,9-dioxa-1,3-diaza-cyclopenta[a]-naphthalen-2-one
03/06/2003US20030045516 Chemokine receptor antagonists and methods of use therefor
03/06/2003US20030045432 Phenyl-substituted cyclic ketoenols
03/06/2003US20030044399 Method of treatment
03/05/2003EP1288203A1 Cyclic nitrones and pharmaceutical compositions containing them
03/05/2003EP1287004A1 Synthetic process for the manufacture of an ecteinascidin compound
03/05/2003EP1287002A1 Crf receptor antagonists
03/05/2003EP1286999A1 PYRANO[2,3-c]IMIDAZO[1,2-a]PYRIDINE DERIVATIVES FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS
03/05/2003EP1286998A1 Oxazolidinone derivatives with antibiotic activity
03/05/2003EP1286994A1 Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
03/05/2003EP1286978A1 Cyclohexyl derivatives and their use as therapeutic agents
03/05/2003EP1286973A2 Novel carbamates and carbamides, production and use thereof as endothelin receptor antagonists
03/05/2003EP1286967A1 Cyclohexane derivatives and their use as therapeutic agents
03/05/2003EP0792273B1 Bicyclic oxazine and thiazine oxazolidinone antibacterials
03/05/2003EP0690863B1 Tetracyclic compounds as dopamine agonists
03/05/2003CN1400969A Fused imidazolium derivatives
02/2003
02/27/2003WO2003016310A1 Alkyl-substituted imidazopyridines for the treatment of gastrointestinal disorders
02/27/2003WO2002098865A3 Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses thereof
02/27/2003WO2002098350A3 Pyranoindazoles and their use for the treatment of glaucoma
02/27/2003WO2002096881A8 Method for preparation of 10,11-dihydro-10-hydroxy-5h-dibenz/b,f/azepine-5-carboxamide and 10,11-dihydro-10-0x0-5h-dibenz/b,f/azepine-5-carboxamide
02/27/2003WO2002092602A3 PROCESSES FOR THE SYNTHESIS OF DERIVATIVES OF 2,3-DIHYDRO-1,4-DIOXINO-[2,3-f] QUINOLINE
02/27/2003WO2002092588A3 Aromatic sulfone hydroxamates and their use as protease inhibitors
02/27/2003WO2002089782A3 Dioxanes and uses thereof
02/27/2003WO2002086878A3 Optical data carrier whose information layer contains a light-absorbing compound having a number of chromophoric centers
02/27/2003WO2002060904A3 A process for the preparation of epothilone analogs
02/27/2003US20030040630 Method for producing sulfonyl imidazole derivatives
02/27/2003US20030037701 2-(aminomethyl)-tetrahydro-9-oxa-1,3-diaza-cyclopenta[a]-naphthalenyl derivatives with antipsychotic activity
02/27/2003CA2452801A1 Alkyl-substituted imidazopyridines for the treatment of gastrointestinal disorders
02/26/2003EP1112456B1 Tube for lining pipes and channels, and a method and device for the production thereof
02/26/2003EP0754040B1 Rapamycin derivatives
02/26/2003CN1398863A Benzo [b] pyran-[3,2-h] acridinyl-7-one compounds, their prepn and medicine composition containing them
02/25/2003US6525197 Producing chemical intermediates for such as epothilone or epothilone analogues synthesis
02/25/2003US6525193 Aminoaryl oxazolidinone N-oxides
02/25/2003US6525047 Which are growth hormone secretogogues and increase the level of endogenous growth hormone; treating osteoporosis, congestive heart failure, frailty associated with aging, obesity; accelerating bone fracture repair
02/20/2003WO2003014124A1 Substituted 5,6,6a,11b-tetrahydro-7-oxa-5-aza-benzo[c]fluorene-6-carboxylic acid derivatives serving as nmda antagonists
02/20/2003WO2003014123A1 Tricyclic imidazopyridines
02/20/2003WO2003014120A1 Amino-substituted imidazopyridines for the treatment of gastrointestinal diseases
02/20/2003WO2003014119A1 Tricyclic epoxides
02/20/2003WO2003014083A1 Spiro compounds
02/20/2003WO2003014069A1 Fluoro linkers and their use as linkers for enzyme-activated drug conjugates
02/20/2003WO2003013537A2 Irinotecan for treatment of cancer
02/20/2003WO2003013536A2 Methods for treatment of cancer using irinotecan based on ugt1a1
02/20/2003WO2003013535A2 Use of irinotecan for improved treatment of cancer based on mdr1
02/20/2003WO2003013534A2 Methods for the treatment of cancer with irinotecan based on cyp3a5
02/20/2003WO2003013533A2 Methods for improved treatment of cancer with irinotecan based on mrp1
02/20/2003WO2003013530A2 Salts of substituted 1, 2, 3, 4-tetrahydroquinoline-2-carboxylic acid derivatives as nmda antagonists
02/20/2003WO2003013522A1 Preventives/remedies for cholinergic neuropathy
02/20/2003WO2003013430A2 Benzoquinone ansamycins
02/20/2003WO2002070525A3 Nitrogen-based camptothecin derivatives
02/20/2003WO2002068387A3 Acylated piperidine derivatives as melanocortin-4 receptor agonists
02/20/2003US20030036652 Spiro[isobenzofuran-1,4'-piperidin]-3-ones and 3H-spiroisobenzofuran-1,4'-piperidines
02/20/2003US20030036543 Especially as inhibitors of Aurora-2 and GSK-3, for treating diseases such as cancer, diabetes and Alzheimer's disease.
02/20/2003CA2456599A1 Spiro compounds
02/20/2003CA2456594A1 Preventives/remedies for cholinergic neuropathy
02/20/2003CA2456175A1 Benzoquinone ansamycins
02/20/2003CA2456124A1 Substituted 5,6,6a,11b-tetrahydro-7-oxa-5-aza-benzo[c]fluorene-6-carboxylic acid derivatives serving as nmda antagonists
02/20/2003CA2456103A1 Salts of substituted 1, 2, 3, 4-tetrahydroquinoline-2-carboxylic acid derivatives
02/20/2003CA2454648A1 Irinotecan for treatment of cancer
02/20/2003CA2454643A1 Methods for the treatment of cancer with irinotecan based on cyp3a5
02/20/2003CA2454640A1 Methods for treatment of cancer using irinotecan based on ugt1a1
02/20/2003CA2454637A1 Use of irinotecan for improved treatment of cancer based on mdr1
02/20/2003CA2454627A1 Methods for improved treatment of cancer with irinotecan based on mrp1
02/20/2003CA2453245A1 Fluoro linkers and their use as linkers for enzyme-activated drug conjugates
02/20/2003CA2452803A1 Tricyclic imidazopyridines
02/20/2003CA2452802A1 Tricyclic epoxides
02/19/2003EP1283855A1 Stable near-infrared (nir) marker dyes based on benzopyrylium-polymethines
02/19/2003EP1283834A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
02/19/2003EP1283833A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
02/19/2003EP1283832A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
02/19/2003EP1283831A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
02/19/2003EP1119571B1 Tricyclic delta3-piperidines as alpha2-antagonists
02/19/2003EP0931083B1 Process for producing ecteinascidin compounds
02/19/2003EP0920429B1 Substituted pyrido- or pyrimido-containing 6,6- or 6,7-bicyclic derivatives
02/19/2003EP0817786B1 Substituted tetronic acids useful for treating hiv and other retroviruses
02/19/2003EP0799218B1 Diaryl-2-(5h)-furanones as cox-2 inhibitors
02/19/2003EP0750618B1 Oxazolidinone derivatives and pharmaceutical compositions containing them
02/19/2003CN1101818C Novel water-soluble c-ring analogues of 20(s)-campothecin
02/18/2003US6521757 Preparation of fused polycyclic alkaloids by ring closure of azomethine ylides, novel compounds thereof and their use as chemotherapeutic agents
02/18/2003US6521753 Indolinospiropyran compounds and methods for their manufacture
1 ... 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 ... 298